Abstract
Neutralizing antibodies have been proven to be highly effective in treating mild and moderate COVID-19 patients, but continuous emergence of SARS-CoV-2 variants poses significant challenges. Antibody cocktail treatments reduce the risk of escape mutants and resistance. In this study, a new cocktail composed of two highly potent neutralizing antibodies (HB27 and H89Y) was developed, whose binding epitope is different from those cocktails that received emergency use authorization. This cocktail showed more potent and balanced neutralizing activities (IC50 0.9–11.3 ng mL−1) against a broad spectrum of SARS-CoV-2 variants over individual HB27 or H89Y antibodies. Furthermore, the cocktail conferred more effective protection against the SARS-CoV-2 Beta variant in an aged murine model than monotherapy. It was shown to prevent SARS-CoV-2 mutational escape in vitro and effectively neutralize 61 types of pseudoviruses harbouring single amino acid mutation originated from variants and escape strains of Bamlanivimab, Casirivimab and Imdevimab with IC50 of 0.6–65 ng mL−1. Despite its breadth of variant neutralization, the HB27+H89Y combo and EUA cocktails lost their potencies against Omicron variant. Our results provide important insights that new antibody cocktails covering different epitopes are valuable tools to counter virus mutation and escape, highlighting the need to search for more conserved epitopes to combat Omicron.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.M., et al. (2022). Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med 386, 1532–1546.
Baum, A., Fulton, B.O., Wloga, E., Copin, R., Pascal, K.E., Russo, V., Giordano, S., Lanza, K., Negron, N., Ni, M., et al. (2020). Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science 369, 1014–1018.
Burki, T.K. (2021). Lifting of COVID-19 restrictions in the UK and the Delta variant. Lancet Respir Med 9, e85.
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022a). Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657–663.
Cao, Y., Wang, X., Li, S., Dong, Y., Liu, Y., Li, J., Zhao, Y., and Feng, Y. (2022b). A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a randomized, double-blinded clinical trial. Sci China Life Sci 65, 1677–1679.
Chen, J., Wang, R., Wang, M., and Wei, G.W. (2020). Mutations strengthened SARS-CoV-2 infectivity. J Mol Biol 432, 5212–5226.
Chen, Q., Huang, X.Y., Liu, Y., Sun, M.X., Ji, B., Zhou, C., Chi, H., Zhang, R.R., Luo, D., Tian, Y., et al. (2022). Comparative characterization of SARS-CoV-2 variants of concern and mouse-adapted strains in mice. J Med Virol 94, 3223–3232.
Corti, D., Purcell, L.A., Snell, G., and Veesler, D. (2021). Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086–3108.
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H.M.E., Ginn, H.M., Mentzer, A.J., Tuekprakhon, A., et al. (2022a). SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467–484.e15.
Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook, D., Stuart, D. I., et al. (2022b). Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236.
Deng, X., Garcia-Knight, M.A., Khalid, M.M., Servellita, V., Wang, C., Morris, M.K., Sotomayor-González, A., Glasner, D.R., Reyes, K.R., Gliwa, A.S., et al. (2021). Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell 184, 3426–3437.e8.
Du, L., Yang, Y., and Zhang, X. (2021). Neutralizing antibodies for the prevention and treatment of COVID-19. Cell Mol Immunol 18, 2293–2306.
FDA. (2020). Emergency Use Authorization (EUA) for Bamlanivimab 700 mg and Etesevimab 1400 mg IV Administered Together Center for Drug Evaluation and Research (CDER) Review. U.S. Food & Drug Administration.
FDA. (2022a). Fact sheet for health care providers emergency use authorization (EUA) of Regen-Cov®(casirivimab and imdevimab), U.S. Food and Drug Administration.
FDA. (2022b). Fact sheet for health care providers emergency use authorization (EUA) of bamlanivimab and etesevimab, U.S. Food and Drug Administration.
Fukushi, S., Watanabe, R. and Taguchi, F. (2008). Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. Methods Mol Biol (Clifton, N.J.) 454, 331–338.
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020). Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science 369, 1603–1607.
Hansen, J., Baum, A., Pascal, K.E., Russo, V., Giordano, S., Wloga, E., Fulton, B.O., Yan, Y., Koon, K., Patel, K., et al. (2020). Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010–1014.
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.S., Winkler, M.S., et al. (2022). The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell 185, 447–456.e11.
Jones, B.E., Brown-Augsburger, P.L., Corbett, K.S., Westendorf, K., Davies, J., Cujec, T.P., Wiethoff, C.M., Blackbourne, J.L., Heinz, B.A., Foster, D., et al. (2021). The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med 13, eabf1906.
Li, H., Zhang, Y., Li, D., Deng, Y.Q., Xu, H., Zhao, C., Liu, J., Wen, D., Zhao, J., Li, Y., et al. (2021a). Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein. Sig Transduct Target Ther 6, 389.
Li, H., Zhao, C., Zhang, Y., Yuan, F., Zhang, Q., Shi, X., Zhang, L., Qin, C., and Zheng, A. (2020). Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays. Emerging Microbes Infects 9, 2269–2277.
Li, M., Lou, F., and Fan, H. (2022). SARS-CoV-2 variant Omicron: currently the most complete “escapee” from neutralization by antibodies and vaccines. Sig Transduct Target Ther 7, 28.
Li, Y., Qi, L., Bai, H., Sun, C., Xu, S., Wang, Y., Han, C., Li, Y., Liu, L., Cheng, X., et al. (2021b). Safety, tolerability, pharmacokinetics, and immunogenicity of a monoclonal antibody (SCTA01) targeting SARS-CoV-2 in healthy adults: a randomized, double-blind, placebo-controlled, phase I study. Antimicrob Agents Chemother 65, e0106321.
Liang, K.H., Chiang, P.Y., Ko, S.H., Chou, Y.C., Lu, R.M., Lin, H.T., Chen, W.Y., Lin, Y.L., Tao, M.H., Jan, J.T., et al. (2021). Antibody cocktail effective against variants of SARS-CoV-2. J Biomed Sci 28, 80.
Liu, L., Iketani, S., Guo, Y., Chan, J.F.W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M.S., et al. (2022). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681.
Liu, Q., Qin, C., Liu, M., and Liu, J. (2021). Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infect Dis Poverty 10, 132.
Liu, Y., Liu, J., Plante, K. S., Plante, J. A., Xie, X., Zhang, X., Ku, Z., An, Z., Scharton, D., Schindewolf, C., et al. (2021). The N501Y spike substitution enhances SARS-CoV-2 transmission. bioRxiv, 2021.2003.2008.434499.
Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D.J., Li, S.Y., Li, Y., and He, Y.W. (2020). Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development? Sci China Life Sci 63, 1833–1849.
Piccoli, L., Park, Y.J., Tortorici, M.A., Czudnochowski, N., Walls, A.C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L.E., Bowen, J.E., et al. (2020). Mapping Neutralizing and Immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell 183, 1024–1042.e21.
Pinto, D., Park, Y.J., Beltramello, M., Walls, A.C., Tortorici, M.A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020). Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295.
Plante, J.A., Liu, Y., Liu, J., Xia, H., Johnson, B.A., Lokugamage, K.G., Zhang, X., Muruato, A.E., Zou, J., Fontes-Garfias, C.R., et al. (2021). Spike mutation D614G alters SARS-CoV-2 fitness. Nature 592, 116–121.
Sadoff, J., Le Gars, M., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., de Groot, A. M., Scheper, G., Hendriks, J., et al. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting. medRxiv, 2021.2008.2025.21262569.
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020). A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature 584, 120–124.
Starr, T.N., Greaney, A.J., Addetia, A., Hannon, W.W., Choudhary, M.C., Dingens, A.S., Li, J.Z., and Bloom, J.D. (2021). Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850–854.
Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R., Mulligan, M. J. and Landau, N. R. (2022). Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. eBioMedicine 78.
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H., et al. (2022a). Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant. N Engl J Med 386, 995–998.
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Halfmann, P., Watanabe, S., Maeda, K., et al. (2022b). Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2. N Engl J Med 386, 1475–1477.
Tao, K., Tzou, P.L., Nouhin, J., Gupta, R.K., de Oliveira, T., Kosakovsky Pond, S.L., Fera, D., and Shafer, R.W. (2021). The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet 22, 757–773.
Tseng, H.F., Ackerson, B.K., Luo, Y., Sy, L.S., Talarico, C.A., Tian, Y., Bruxvoort, K.J., Tubert, J.E., Florea, A., Ku, J.H., et al. (2022). Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med 28, 1063–1071.
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J.C., Muecksch, F., Rutkowska, M., Hoffmann, H.H., Michailidis, E., et al. (2020). Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife 9, e61312.
Whitt, M.A. (2010). Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods 169, 365–374.
WHO. (2022). WHO Coronavirus (COVID-19). Dashboard, World Health Organization.
Zhou, B., Zhou, R., Chan, J. F.-W., Luo, M., Peng, Q., Yuan, S., Mok, B. W.-Y., Chen, B., Wang, P., Poon, V. K.-M., et al. (2022). An elite broadly neutralizing antibody protects SARS-CoV-2 Omicron variant challenge. bioRxiv, 2022.2001.2005.475037.
Zhu, L., Deng, Y.Q., Zhang, R.R., Cui, Z., Sun, C.Y., Fan, C.F., Xing, X., Huang, W., Chen, Q., Zhang, N.N., et al. (2021). Double lock of a potent human therapeutic monoclonal antibody against SARS-CoV-2. Natl Sci Rev 8, nwaa297.
Zost, S.J., Gilchuk, P., Case, J.B., Binshtein, E., Chen, R.E., Nkolola, J.P., Schäfer, A., Reidy, J.X., Trivette, A., Nargi, R.S., et al. (2020). Potently neutralizing and protective human antibodies against SARS-CoV-2. Nature 584, 443–449.
Acknowledgements
This work was supported by the National Key Research and Development Project of China (2021YEF0201700).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Sun, C., Chi, H., Yuan, F. et al. An antibody cocktail with broadened mutational resistance and effective protection against SARS-CoV-2. Sci. China Life Sci. 66, 165–179 (2023). https://doi.org/10.1007/s11427-022-2166-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-022-2166-y